newsfilter
← Latest News
Business Wire·

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of activity Confirmed partial response in one patient in the lowes